Stockscreener 앱 받기
72.45
3.65%
2.55
전일 마감가:
$69.90
열려 있는:
$69.94
하루 거래량:
89,459
Relative Volume:
0.54
시가총액:
$803.71M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+6.62%
1개월 성능:
+27.46%
6개월 성능:
+232.95%
1년 성능:
+0.00%
1일 변동 폭
$66.58
$72.81
1주일 범위
$65.93
$76.43
52주 변동 폭
$11.17
$76.43
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
125 STRAFFORD AVE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
72.67 | 773.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.94 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial - MarketScreener
What Fibonacci levels say about Palvella Therapeutics Inc. reboundWall Street Watch & Free Community Supported Trade Ideas - newser.com
Can Palvella Therapeutics Inc. stock rebound after recent weaknessProfit Target & Daily Technical Stock Forecast Reports - newser.com
U.S. FDA awards year two funds to Palvella's phase 3 Selva trial - MarketScreener
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance
Can Palvella Therapeutics Inc. rally from current levelsJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9%What's Next? - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Palvella Therapeutics Inc. reversing from oversold territoryJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Palvella Therapeutics Inc. meeting your algorithmic filter criteriaChart Signals & Long-Term Investment Growth Plans - newser.com
Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication - Investing.com Canada
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Can trapped investors hope for a rebound in Palvella Therapeutics Inc.Quarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - newser.com
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MSN
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighHere's Why - MarketBeat
Tick level data insight on Palvella Therapeutics Inc. volatilityMarket Rally & AI Driven Price Predictions - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stock2025 Price Targets & Long-Term Capital Growth Strategies - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Earnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportTrade Analysis Summary & Detailed Earnings Play Alerts - newser.com
LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Strid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $80 - 富途牛牛
Published on: 2025-10-03 02:03:51 - newser.com
Truist Securities Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00 - MarketBeat
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MSN
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investments2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - 富途牛牛
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Palvella Therapeutics Inc 주식 (PVLA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Apr 09 '25 |
Buy |
20.13 |
2,500 |
50,325 |
183,171 |
| JENKINS GEORGE M | Director |
Dec 18 '24 |
Buy |
12.93 |
4,000 |
51,720 |
180,671 |
1.09%
자본화:
|
볼륨(24시간):